Fintel reports that on December 19, 2025, HC Wainwright & Co. maintained coverage of Pyxis Oncology (NasdaqGS:PYXS) with a Buy recommendation. Analyst Price Forecast Suggests 474.27% Upside As of ...

Investing.com - Truist Securities has raised its price target on Alnylam Pharmaceuticals (NASDAQ:ALNY) to $535 from $459 while ...

Pyxis Oncology (PYXS) completed sale of its rights to royalties from the commercialization of Enzeshu for a one-time cash payment of $11M. This non-dilutive funding will support the development of ...

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Find the latest Pyxis Oncology, Inc. (PYXS) stock quote, history, news and other vital information to help you with your stock trading and investing.